Celiprolol (Celectol – Rhoône Poulenc Rorer) is a new cardioselective β-blocker and vasodilator, intended for once daily treatment of mild to moderate hypertension. The manufacturer claims that “it improves the overall cardiovascular risk profile” and gives hypertensive patients “a better quality of life than can be expected from conventional β-blocker treatment”. We examine these claims.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.